Selected clinical trials of bispecific antibodies in multiple myeloma
| Trial . | Patient . | Intervention . | Phase . |
|---|---|---|---|
| MajesTEC-4 (NCT05243797) | NDMM | Post-autologous stem cell transplant: TEC + Len vs. Len vs. TEC | Phase 3 |
| MajesTEC-5 (NCT05695508) | NDMM transplant eligible | Induction with: TEC + Dara + Len + dex vs. TEC + Bort + Len + Dara + dex vs. Standard of care Followed by: TEC + Dara + Len maintenance | Phase 2 |
| MajesTEC-7 (NCT05552222) | NDMM transplant noneligible | TEC + Dara + Len vs. Dara + Len + dex | Phase 3 |
| MagnetisMM-7 (NCT05317416) | NDMM | Post-autologous stem cell transplant: ELRA vs. Len | Phase 3 |
| MajesTEC-2 (NCT04722146) | NDMM and RRMM | TEC + Dara + Pom vs. TEC + Dara + Pom + Bort (21- or 28-day cycle) vs. TEC + nirogacestat vs. TEC + Len vs. TEC + Dara + Len | Phase 1b |
| MajesTEC-3 (NCT05083169) | RRMM, 1-3 prior lines including PI and Len | TEC + Dara vs. Dara + Pom + dex or Dara + Bort + dex | Phase 3 |
| MajesTEC-9 (NCT05572515) | RRMM, 1-3 prior lines including anti-CD38 and IMiD | TEC vs. Pom + Bort + dex or Carf + dex | Phase 3 |
| MagnetisMM-6 (NCT05623020) | Part 1: RRMM 1-2 prior lines of therapy including IMiD and PI or NDMM transplant noneligible Part 2: NDMM transplant noneligible | ELRA + Dara + Len vs. Dara + Len + dex | Phase 3 |
| MagnetisMM-1 (NCT03269136) | RRMM, triple-class refractory | ELRA vs. ELRA + dex vs. ELRA + Len vs. ELRA + Pom | Phase 1 |
| MagnetisMM-3 (NCT04649359) | RRMM, triple-class refractory Cohort A: no prior anti-BCMA Cohort B: prior anti-BCMA ADC or CAR T | ELRA | Phase 2 |
| MagnetisMM-4 (NCT05090566) | RRMM, triple-class refractory | ELRA + nirogacestat vs. ELRA + Len + dex | Phase 1b/2 |
| MagnetisMM-5 (NCT05020236) | RRMM, prior therapy including IMiD and PI | ELRA vs. ELRA + Dara vs. Dara + Pom + dex | Phase 3 |
| TRIMM-2 (NCT04108195) | RRMM, 3 prior lines including PI and IMiD | TEC + Dara vs. TALQ + Dara vs. TEC + Dara + Pom vs. TALQ + Dara + Pom | Phase 1b |
| RedirecTT-1 (NCT04586426) | RRMM | TALQ + TEC + Dara | Phase 1b |
| TRIMM-3 (NCT05338775) | RRMM | TALQ + TEC + PD-1 inhibitor | Phase 1b |
| MonumenTAL-2 (NCT05050097) | NDMM | TALQ + Carf vs. TALQ + Dara + Carf vs. TALQ + Len vs. TALQ + Dara + Len vs. TALQ + Pom | Phase 1b |
| MonumenTAL-3 (NCT05455320) | RRMM | TALQ + Dara + Pom vs. Dara + Pom + dex vs. TALQ + Dara + dex | Phase 3 |
| IFM 2021-01 (NCT05572229) | Older adults, age ≥65 | TEC + Dara vs. TEC + Len | Phase 2 |
| Immuno-PRISM (NCT05469893) | High-risk SMM | Len/dex vs. TEC | Phase 2 |
| Trial . | Patient . | Intervention . | Phase . |
|---|---|---|---|
| MajesTEC-4 (NCT05243797) | NDMM | Post-autologous stem cell transplant: TEC + Len vs. Len vs. TEC | Phase 3 |
| MajesTEC-5 (NCT05695508) | NDMM transplant eligible | Induction with: TEC + Dara + Len + dex vs. TEC + Bort + Len + Dara + dex vs. Standard of care Followed by: TEC + Dara + Len maintenance | Phase 2 |
| MajesTEC-7 (NCT05552222) | NDMM transplant noneligible | TEC + Dara + Len vs. Dara + Len + dex | Phase 3 |
| MagnetisMM-7 (NCT05317416) | NDMM | Post-autologous stem cell transplant: ELRA vs. Len | Phase 3 |
| MajesTEC-2 (NCT04722146) | NDMM and RRMM | TEC + Dara + Pom vs. TEC + Dara + Pom + Bort (21- or 28-day cycle) vs. TEC + nirogacestat vs. TEC + Len vs. TEC + Dara + Len | Phase 1b |
| MajesTEC-3 (NCT05083169) | RRMM, 1-3 prior lines including PI and Len | TEC + Dara vs. Dara + Pom + dex or Dara + Bort + dex | Phase 3 |
| MajesTEC-9 (NCT05572515) | RRMM, 1-3 prior lines including anti-CD38 and IMiD | TEC vs. Pom + Bort + dex or Carf + dex | Phase 3 |
| MagnetisMM-6 (NCT05623020) | Part 1: RRMM 1-2 prior lines of therapy including IMiD and PI or NDMM transplant noneligible Part 2: NDMM transplant noneligible | ELRA + Dara + Len vs. Dara + Len + dex | Phase 3 |
| MagnetisMM-1 (NCT03269136) | RRMM, triple-class refractory | ELRA vs. ELRA + dex vs. ELRA + Len vs. ELRA + Pom | Phase 1 |
| MagnetisMM-3 (NCT04649359) | RRMM, triple-class refractory Cohort A: no prior anti-BCMA Cohort B: prior anti-BCMA ADC or CAR T | ELRA | Phase 2 |
| MagnetisMM-4 (NCT05090566) | RRMM, triple-class refractory | ELRA + nirogacestat vs. ELRA + Len + dex | Phase 1b/2 |
| MagnetisMM-5 (NCT05020236) | RRMM, prior therapy including IMiD and PI | ELRA vs. ELRA + Dara vs. Dara + Pom + dex | Phase 3 |
| TRIMM-2 (NCT04108195) | RRMM, 3 prior lines including PI and IMiD | TEC + Dara vs. TALQ + Dara vs. TEC + Dara + Pom vs. TALQ + Dara + Pom | Phase 1b |
| RedirecTT-1 (NCT04586426) | RRMM | TALQ + TEC + Dara | Phase 1b |
| TRIMM-3 (NCT05338775) | RRMM | TALQ + TEC + PD-1 inhibitor | Phase 1b |
| MonumenTAL-2 (NCT05050097) | NDMM | TALQ + Carf vs. TALQ + Dara + Carf vs. TALQ + Len vs. TALQ + Dara + Len vs. TALQ + Pom | Phase 1b |
| MonumenTAL-3 (NCT05455320) | RRMM | TALQ + Dara + Pom vs. Dara + Pom + dex vs. TALQ + Dara + dex | Phase 3 |
| IFM 2021-01 (NCT05572229) | Older adults, age ≥65 | TEC + Dara vs. TEC + Len | Phase 2 |
| Immuno-PRISM (NCT05469893) | High-risk SMM | Len/dex vs. TEC | Phase 2 |
ADC, antibody drug conjugate; Bort, bortezomib; Carf, carfilzomib; Dara, daratumumab; dex, dexamethasone; ELRA, elranatamab; IMiD, immunomodulatory drug; Len, lenalidomide; NDMM, newly diagnosed multiple myeloma; PI, proteasome inhibitor; Pom, pomalidomide; RRMM, relapsed refractory multiple myeloma; SMM, smouldering multiple myeloma; TALQ, talquetamab; TEC, teclistamab.